• Home
  • About Us
  • Science
    • Active Immunotherapies
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

AACR (American Association for Cancer Research) Annual Meeting, April 2025, Chicago, Illinois

by alex | May 2, 2025 | Immunobody, SCIB1

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples,Kate Young, Pippa Corrie, Robert Miller, Georgia Goodhew, Samantha Paston, Gaelle Cane, Joe Chadwick, Lindy Durrant and...

AACR 10 (American Association for Cancer Research), February 2025, Los Angeles, California

by chantal | Mar 12, 2025 | Immunobody, SCIB1

Joseph Chadwick, Gaëlle Cane, Sabaria Shah, Katie Mann, Patrick Copeland, Daisy Weston, Jordan Wright, Leanne Toon, Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples,...

Scancell announces further positive data from the ongoing SCOPE trial of SCIB1 with double CPIs for Advanced Melanoma

by chantal | Nov 18, 2024 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial

by admin | Jul 24, 2024 | iSCIB1+, Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

by admin | Jun 18, 2024 | Interviews, Latest News, Media Coverage, Modi-1, SCIB1

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer Scancell’s Chief Executive Officer, Lindy Durrant, recently sat down with Sarah Lowther from focusIR. During the interview Lindy highlights Scancell’s innovative...

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024

by chantal | Jun 11, 2024 | Modi-1, SCIB1, Vaccines

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma Samantha Paston, Heather Shaw, Poulam Patel, Miranda...
« Older Entries
Next Entries »

Recent Posts

  • ESMO IO: Refining Standard of Care in Advanced Melanoma
  • CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive
  • SCOPE Data Update: 11 December 2025
  • European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London
  • Latest SCOPE data confirm durable improvement

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy